Top Tech Companies in Dublin (1,357)

Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.

Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.

Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.

Strong Revenue Growth: Recent filings and press coverage indicate sharp growth in total revenues and fee revenues, with fee-related earnings also expanding despite quarterly variability.

Strong Market Position & Advantage: Disclosures consistently frame the firm as a leader in private‑markets solutions with large AUM/AUA scale, multi‑asset breadth, and influence via its SPI data and benchmarks.

Strategic Partnerships: Partnerships with LSEG/FTSE, Kroll, and PitchBook to distribute private‑markets indices and benchmarks expand reach and reinforce its role as a reference point for LPs and GPs.

Investor Backing & Capital Strength: Recent financing at a unicorn valuation provides substantial capital to scale product and go-to-market. Public funding events signal strong investor confidence in the company’s category leadership potential.

Strong Revenue Growth: Audited results indicate revenue increased sharply year over year into early 2025, with leadership describing momentum as steady into 2026. Reported gains stem from both new-customer additions and expansion within existing accounts.

Strategic Partnerships: Expansion of the partner ecosystem and materially partner-led revenue contribution in North America indicate a leverageable channel for scale. Growing channel and technology relationships broaden implementation reach and market access.

Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.

Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.

Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.

Strong Market Position & Advantage: Feedback suggests KBRA holds leading shares in key U.S. structured‑finance niches—especially CMBS—reinforced by Bloomberg’s CMBS index inclusion and SEC data on agency CMBS leadership. Industry awards naming it Securitization/ABS/CMBS Rating Agency of the Year indicate entrenched influence among market participants.

Market Expansion: Feedback suggests KBRA’s footprint is widening via SEC NRSRO status and recognition across the U.S., EU, UK, and Canada, plus office growth in Dublin and Tokyo and index‑methodology integrations that increase downstream use. These moves signal deliberate entry into new geographies and investor workflows.

Product Line Growth: Feedback suggests KBRA is broadening beyond CMBS into ABS, structured credit, and private credit/fund finance, including rising subscription‑line activity and a new corporate portfolio finance/direct lending unit. Reported annual issuance handled and frequent outlooks/surveillance point to an expanding product set and engagement.

Strong Market Position & Advantage: Analog Devices is positioned as a top-tier analog and mixed-signal semiconductor provider with leadership in key niches like data converters and a “premium position” in complex, high-performance analog. Its design-in “stickiness” in long-lifecycle systems is described as supporting predictable, long-term revenue.

Strong Revenue Growth: Recent results show a rebound and acceleration, including fiscal 2025 revenue growth versus 2024 and strong year-over-year growth in the most recent quarter with higher near-term revenue guidance. Forward-looking expectations also indicate continued expansion over the next several years.

Healthy Cash Flow: Cash generation is described as robust, with strong operating and free cash flow enabling sizable shareholder returns through dividends and repurchases. Ongoing dividend increases are presented as consistent with confidence in durable cash generation.

Strong Market Position & Advantage: Kaseya is portrayed as a leading vendor in MSP-focused RMM/PSA and BCDR, having overtaken a key rival in market share and maintaining a prominent role in the MSP community. Feedback suggests its long-standing presence and industry events further reinforce its positioning.

Product Line Growth: The portfolio has expanded through acquisitions and integrations (e.g., Datto assets, email security additions, and SaaS Alerts) alongside launches like Kaseya 365. Feedback suggests this broadening stack aims to deliver a more comprehensive, integrated platform for MSPs.

Strong Revenue Growth: Revenue and adoption indicators in the snippets point to substantial multi‑year growth, with notable momentum in the RMM/PSA segment. Acquisitions and bundling are described as contributing to accelerated commercial performance.

Strong Market Position & Advantage: SumUp is positioned as a top-tier provider for micro‑merchants in Europe, with regulators placing it among the largest European mPOS providers by transaction volume. The company also reports large-scale adoption, serving 4+ million merchants across 35+ markets and processing 1+ billion transactions annually.

Investor Backing & Capital Strength: Access to sizable financing is evidenced by a €285M raise in Dec 2023 and a €1.5B private‑credit facility in May 2024, supporting continued expansion and potential M&A. Prior fundraising at an ~€8–8.5B valuation further signals meaningful capital support even in a tougher fintech funding environment.

Profitability: Profitability momentum is indicated by company statements that it has been EBITDA‑positive since Q4 2022 with continued margin improvement through 2023–2024. This suggests growth has been accompanied by improving operating leverage rather than purely top‑line expansion.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Profitability: Strong earnings power is indicated by a robust return on equity in 2024 alongside solid capital ratios, supporting resilience through market cycles.

Strategic Partnerships: Strategic collaborations and alliances (e.g., BBH Credit Partners with AMG and the alliance with SimCorp) indicate continued investment in distribution and service capabilities rather than reliance on large acquisitions.

Resilient & Sustainable Growth: Organic momentum is reflected in rising AUCA/AUM checkpoints, record ETF-launch activity, and recurring mandate wins, suggesting growth driven by client activity and secular tailwinds in ETFs and private markets.

Strong Revenue Growth: Recent quarters show double‑digit top‑line increases, a first billion‑dollar quarter, and raised annual guidance, indicating momentum. Rising backlog and growing subscription ARR further support continued expansion.

Diversified Revenue Streams: The mix is shifting toward subscriptions and as‑a‑service models alongside product sales, with consumption offerings gaining traction. Cloud collaborations and platform services expand monetization beyond one‑time hardware transactions.

Strong Market Position & Advantage: Independent analyst reports place the company in the Leader cohort for primary/enterprise storage, often highest on execution and vision. This standing helps it compete effectively and be routinely shortlisted against large incumbents in mission‑critical procurements.